Insider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 10,000 Shares of Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 10,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $11.39, for a total value of $113,900.00. Following the transaction, the senior vice president owned 326,918 shares of the company's stock, valued at approximately $3,723,596.02. This trade represents a 2.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Rhonda Farnum also recently made the following trade(s):

• On Monday, July 14th, Rhonda Farnum sold 10,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $11.39, for a total value of $113,900.00.
• On Monday, June 2nd, Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $11.00, for a total value of $264,000.00.
• On Monday, April 21st, Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock. The shares were sold at an average price of $9.00, for a total value of $36,000.00.

Theravance Biopharma Stock Performance

NASDAQ:TBPH traded down $0.37 during mid-day trading on Friday, hitting $11.25. The company had a trading volume of 144,416 shares, compared to its average volume of 257,811. Theravance Biopharma, Inc. has a fifty-two week low of $7.44 and a fifty-two week high of $11.88. The business's fifty day moving average is $10.47 and its two-hundred day moving average is $9.67. The firm has a market cap of $562.51 million, a P/E ratio of -9.53 and a beta of -0.02.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The business had revenue of $15.39 million for the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. Equities analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on TBPH shares. BTIG Research upped their price target on Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, June 27th. Wall Street Zen cut Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Finally, Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price on the stock in a report on Tuesday, June 17th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $16.60.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TBPH. Rhumbline Advisers raised its holdings in Theravance Biopharma by 3.8% in the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company's stock valued at $556,000 after acquiring an additional 2,293 shares in the last quarter. Geode Capital Management LLC raised its holdings in Theravance Biopharma by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company's stock valued at $8,121,000 after acquiring an additional 4,823 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Theravance Biopharma by 16.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 64,795 shares of the biopharmaceutical company's stock valued at $610,000 after acquiring an additional 9,315 shares in the last quarter. ProShare Advisors LLC acquired a new position in Theravance Biopharma in the 4th quarter valued at $119,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Theravance Biopharma by 27.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,039 shares of the biopharmaceutical company's stock valued at $1,412,000 after acquiring an additional 32,534 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.